Close

Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 2 Met Primary Endpoint in T2D

Go back to Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 2 Met Primary Endpoint in T2D